Damandeep Walia
Allergy & Immunology · Kansas City, KSNPI 1225160674
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,250 of the $2,684 with a category attached, or 83.8%. Amgen accounts for 89.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $2,330 and has fallen 99.2% since, to $18 in 2025.
Across 15 payments — averaging $178.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$127
- Johnson & Johnson$103
- AbbVie$29
- UCB, Inc.$18
Across 3 payments — averaging $53,367 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$160K
What the payments were for
- Speaking & faculty fees$2,25084%
- Travel & lodging$281%
- Food & beverage$35213%
- Education$552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 7 | $2,407 |
| AstraZeneca(2 entities) | 2 | $127 |
| Johnson & Johnson | 4 | $103 |
| AbbVie | 1 | $29 |
| UCB, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$2,250
How this compares
$2,684 in reported general payments places this provider in the 55th percentile of 33 allergy & immunology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KevzaraSarilumab | 13 | $58,431 |
| Hydroxychloroquine Sulfate | 95 | $2,807 |
| MethotrexateMethotrexate Sodium | 85 | $2,049 |
| Leflunomide | 28 | $769 |
| Prednisone | 112 | $465 |
| Meloxicam | 17 | $257 |
| Sulfasalazine | 19 | $120 |
| Azathioprine | 11 | $118 |
| Allopurinol | 15 | $68 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Kansas City
- Selina GiererKansas City$13K
- Marissa LoveKansas City$4K
- Hanh HoKansas City$2K
- Jeehyun RhaKansas City$1K
- Timothy NguyenKansas City$743
- Tomara SpiessKansas City$455
- Andrea D'melloKansas City$371
- John MartinezKansas City$76
- Henry KanarekOverland Park$143K
- Celina BernabeOverland Park$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.